The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Tereza Planck

Physician

Default user image.

Serum CYR61 Levels are Associated with Graves' Ophthalmopathy and Smoking in Patients with Graves' Disease

Author

  • Perparim Cerri
  • Bushra Shahida
  • Mikael Lantz
  • Tereza Planck

Summary, in English

Smoking is a well-known risk factor for Graves' ophthalmopathy (GO) in patients suffering from Graves' disease (GD). Cysteine-rich angiogenic inducer 61 (CYR61), which has multiple physiological functions, has been shown to be associated with GD and GO. In this study, we aimed to investigate the association between smoking and CYR61 concentrations in GD patients with and without GO. Serum CYR61 was measured by ELISA. The association between CYR61 concentration and GO was assessed with binary logistic regression in all patients and in subgroups of smokers and nonsmokers. The Spearman correlation coefficient was used to determine the correlations between CYR61 concentration and clinical parameters. CYR61 levels were significantly higher in GD patients with GO than in patients without GO, in smokers than in nonsmokers and in individuals older than 50 years than in those younger than 50 years. The subgroup of GO smokers had the highest CYR61 levels [median (IQR), 119 pg/ml (129.8)], compared with GO nonsmokers [84.2 pg/ml (90.8), p=0.04], no GO smokers [88.9 pg/ml (109.8), p=0.01] and no GO nonsmokers [79.4 pg/ml (129.89), p=0.003]. For each unit increase in CYR61 concentration, the odds of having GO in smokers significantly and independently increased by 1% (OR=1.010; 95% CI: 1.002-1.018, p=0.012). In conclusion, our results indicate that smoking and age increase serum CYR61 levels in patients with GD and GO. The role of CYR61 as a predictor of GO in patients with GD should be evaluated in prospective studies.

Department/s

  • Genomics, Diabetes and Endocrinology
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2021-03-01

Language

English

Pages

168-174

Publication/Series

Hormone and Metabolic Research

Volume

54

Issue

3

Document type

Journal article

Publisher

Georg Thieme Verlag

Topic

  • Endocrinology and Diabetes

Keywords

  • CCN1
  • CYR61
  • Graves' disease
  • Graves' ophthalmopathy
  • immediate early genes
  • smoking

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 0018-5043